

RSV Vaccine and mAb Snapshot

TARGET INDICATION: P = PEDIATRIC M = MATERNAL E = ELDERLY

	PRECLINICAL				PHASE 1			PHASE 2		PHASE 3	MARKET APPROVED
LIVE-ATTENUATED/CHIMERIC	Codagenix, LID/NIAID/NIH RSV	LID/NIAID/NIH RSV			Intravacc ^P Delta-G RSV	Sanofi, LID/NIAID/NIH RSV ΔNS2/Δ1313/11314L ^P	Sanofi, LID/NIAID/NIH RSV 6120/ΔNS2/1030s ^P				
	LID/NIAID/NIH PIV1-3/RSV	Meissa Vaccines RSV			Pontificia Universidad Catolica de Chile BCG/RSV ^P	Sanofi, LID/NIAID/NIH RSV D46/NS2/N/ΔM2-2-HindIII ^P	SIPL, St. Jude Hospital SeV/RSV ^P				
WHOLE-INACTIVATED	Blue Willow Biologics RSV										
PARTICLE-BASED	AgilVax VLP	Fraunhofer VLP	TechnoVax VLP	VBI Vaccines VLP	Novavax ^P RSV F Nanoparticle			Novavax ^E RSV F Nanoparticle		Novavax ^M RSV F Nanoparticle	
	Artificial Cell Technologies Peptide microparticle	Georgia State University VLP	University of Massachusetts VLP	Virometix VLP							
SUBUNIT	Instituto de Salud Carlos III RSV F Protein	University of Georgia RSV G Protein			Beijing Advaccine Biotechnology RSV G Protein ^{P E}	Immunovaccine, VIB DPX-RSV-SH Protein ^E	NIH/NIAID/VRC RSV F Protein ^{E M}	Pfizer ^{E M} RSV F Protein			
	Sciogen RSV G Protein	University of Saskatchewan RSV F Protein			GlaxoSmithKline ^{E M} RSV F Protein	Janssen Pharmaceutical ^E RSV F Protein					
NUCLEIC ACID	CureVac RNA	Inovio Pharmaceuticals DNA									
RECOMBINANT VECTORS	BravoVax Adenovirus				Vaxart ^E Adenovirus			Bavarian Nordic ^E MVA	Janssen Pharmaceutical ^{P E} Adenovirus		
								GlaxoSmithKline ^P Adenovirus			
IMMUNO-PROPHYLAXIS/COMBINATION	Arsanis Anti-F mAb	Biomedical Research Models DNA prime, Particle boost	Pontificia Universidad Catolica de Chile Anti-N mAb	UCAB, mAbXience Anti-F mAb	Merck ^P Anti-F mAb			MedImmune, Sanofi ^P Anti-F mAb		MedImmune ^P Synagis	

UPDATED: December 10, 2018

Indicates Change

<http://vaccineresources.org/details.php?i=1562>

